{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:45:49Z","timestamp":1759041949546,"version":"3.41.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>The pyridobenzoxazepine compound, 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13), has been developed as a potential antipsychotic drug. We tested the hypothesis that JL13 is efficacious in both dopaminergic and glutamatergic animal models of schizophrenia. We investigated JL13 for its efficacy to prevent cocaine- and ketamine-induced hyperlocomotion and MK-801-induced deficits in prepulse inhibition (PPI) of the startle reflex. Male Swiss mice received injections of JL13 (0.1\u201310 mg\/kg) and were tested in the open field for basal locomotion. In separate experiments, the animals received injections of JL13 (0.1\u20133 mg\/kg) followed by cocaine (10 mg\/kg), ketamine (60 mg\/kg), or MK-801 (0.5 mg\/kg) and were tested in the open field for hyperlocomotion. In addition, it was also tested if JL13 prevented MK-801-induced disruption of PPI. Only the highest dose of JL13 impaired spontaneous locomotion, suggesting its favorable profile regarding motor side effects. At doses that did not impair basal motor activity, JL13 prevented cocaine-, ketamine-, and MK-801-induced hyperlocomotion. Moreover, JL13 prevented MK-801-induced disruption of PPI. Extending previous findings, this study shows that JL13 exerts antipsychotic-like activity in both dopaminergic and glutamatergic models. This compound has a favorable pharmacological profile, similar to second-generation antipsychotics.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000595","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T03:40:00Z","timestamp":1609472400000},"page":"2-8","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity"],"prefix":"10.1097","volume":"32","author":[{"given":"Yane C.P.","family":"Andrade","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Institute of Biological Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jivago","family":"Ropke","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Biological Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9rcia G.","family":"Viana","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Biological Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fanelli","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Biological Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Minaldi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Biological Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luara A.","family":"Batista","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Graduate School in Neuroscience, Universidade Federal de Minas Gerais, Belo Horizonte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"Issy","sequence":"additional","affiliation":[{"name":"Departament of Morphology, Estomatology and Basic Pathology, Faculty of Odontology of Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo Ribeir\u00e3o Preto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine A.","family":"Del Bel","sequence":"additional","affiliation":[{"name":"Departament of Morphology, Estomatology and Basic Pathology, Faculty of Odontology of Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo Ribeir\u00e3o Preto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00edvia C.M.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, Health Science Center, Universidade Federal do Esp\u00edrito Santo, Vit\u00f3ria, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Li\u00e9geois","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Laboratory of Medicinal Chemistry, Faculty of Medicine and CIRM, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabr\u00edcio A.","family":"Moreira","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Biological Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00008877-199212000-00004","article-title":"Comparative study of typical neuroleptics, clozapine and newly synthesized clozapine-analogues: correlations between neurochemistry and behaviour.","volume":"3","author":"Bruhwyler","year":"1992","journal-title":"Behav Pharmacol"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/phrs.1997.0231","article-title":"JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties.","volume":"36","author":"Bruhwyler","year":"1997","journal-title":"Pharmacol Res"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/0929867043456034","article-title":"Schizophrenia: from dopamine to glutamate and back.","volume":"11","author":"Carlsson","year":"2004","journal-title":"Curr Med Chem"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s002130100808","article-title":"The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.","volume":"157","author":"Casey","year":"2001","journal-title":"Psychopharmacology (BERL)"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00210-018-1500-x","article-title":"Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity.","volume":"391","author":"da Silveira","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"108047","DOI":"10.1016\/j.neuropharm.2020.108047","article-title":"Early postnatal l-Dopa treatment causes behavioral alterations in female vs. male young adult Swiss mice.","volume":"170","author":"de Matos","year":"2020","journal-title":"Neuropharmacology"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1527-3458.2003.tb00243.x","article-title":"JL 13, an atypical antipsychotic: a preclinical review.","volume":"9","author":"Ellenbroek","year":"2003","journal-title":"CNS Drug Rev"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0022-3565(24)29392-7","article-title":"Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia.","volume":"298","author":"Ellenbroek","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00213-006-0658-y","article-title":"The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.","volume":"191","author":"Fejgin","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00441-013-1599-5","article-title":"Translational value of startle modulations.","volume":"354","author":"Fendt","year":"2013","journal-title":"Cell Tissue Res"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview.","volume":"172","author":"Gardner","year":"2005","journal-title":"CMAJ"},{"issue":"Suppl 2","key":"R12-20250614","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs.","volume":"35","author":"Gobira","year":"2013","journal-title":"Braz J Psychiatry"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia.","volume":"174","author":"Goff","year":"2017","journal-title":"Am J Psychiatry"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century.","volume":"29","author":"Howes","year":"2015","journal-title":"J Psychopharmacol"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.","volume":"15","author":"Howes","year":"2009","journal-title":"Curr Pharm Des"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.bbr.2009.08.003","article-title":"Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice.","volume":"205","author":"Issy","year":"2009","journal-title":"Behav Brain Res"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2004.06.005","article-title":"How antipsychotics become anti-\u201cpsychotic\u201d \u2013 from dopamine to salience to psychosis.","volume":"25","author":"Kapur","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors.","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2005.01.003","article-title":"From dopamine to salience to psychosis\u2013linking biology, pharmacology and phenomenology of psychosis.","volume":"79","author":"Kapur","year":"2005","journal-title":"Schizophr Res"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coph.2014.01.001","article-title":"Schizophrenia: from dopaminergic to glutamatergic interventions.","volume":"14","author":"Laruelle","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2007.09.016","article-title":"Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.","volume":"578","author":"Leite","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(01)02539-3","article-title":"Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats.","volume":"319","author":"Li\u00e9geois","year":"2002","journal-title":"Neurosci Lett"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1021\/jm2013419","article-title":"New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.","volume":"55","author":"Li\u00e9geois","year":"2012","journal-title":"J Med Chem"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1006\/bbrc.1997.7270","article-title":"JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena.","volume":"238","author":"Li\u00e9geois","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1021\/jm00030a011","article-title":"Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.","volume":"37","author":"Li\u00e9geois","year":"1994","journal-title":"J Med Chem"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia.","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","article-title":"The dopamine hypothesis of schizophrenia: a review.","volume":"2","author":"Meltzer","year":"1976","journal-title":"Schizophr Bull"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archpsyc.1972.01750260021004","article-title":"Catecholamines in the brain as mediators of amphetamine psychosis.","volume":"27","author":"Snyder","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/0269881116661075","article-title":"Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next.","volume":"30","author":"Swerdlow","year":"2016","journal-title":"J Psychopharmacol"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12031-007-0034-3","article-title":"Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors.","volume":"32","author":"Tarazi","year":"2007","journal-title":"J Mol Neurosci"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia.","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bcpt.12036","article-title":"Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice.","volume":"112","author":"Viana","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.","volume":"159","author":"Volavka","year":"2002","journal-title":"Am J Psychiatry"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:04:16Z","timestamp":1749938656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000595","relation":{},"ISSN":["0955-8810"],"issn-type":[{"type":"print","value":"0955-8810"}],"subject":[],"published":{"date-parts":[[2020,12,29]]}}}